Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc reported significant advancements in its human and animal health programs for the first half of 2025. The company has repositioned its lead compound, GF-1002, to address advanced stages of MASH, a chronic liver disease with limited treatment options, highlighting a substantial commercial opportunity. Additionally, Genflow is exploring SIRT6-based therapies in ophthalmology and conducting a clinical trial in dogs to test GF-1004 for sarcopenia. The integration of human and animal health initiatives is expected to strengthen Genflow’s position in healthspan science, with financial stability supported by recent equity fundraising and ongoing efforts to secure non-dilutive funding.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on developing gene therapies to slow the aging process. Their lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, aiming to promote longer and healthier lives. The company is actively working on programs targeting both human and animal health, including clinical trials for age-related diseases such as MASH and sarcopenia.
Average Trading Volume: 7,221,271
Technical Sentiment Signal: Buy
For a thorough assessment of GENF stock, go to TipRanks’ Stock Analysis page.